Sanofi to Acquire UK Vaccine Firm Vicebio in $1.6B Deal to Boost Respiratory Portfolio

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal valued at up to $1.6 billion, aiming to expand its pipeline of respiratory vaccines. The agreement includes an upfront payment of $1.15 billion, with an additional $450 million tied to development and regulatory milestones.

Vicebio specializes in respiratory vaccine research and has developed two promising early-stage vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). These viruses are significant causes of respiratory illness, particularly in young children and older adults. Sanofi’s acquisition is part of its strategic push to strengthen its position in the competitive respiratory vaccine market.

A key component of the deal is Vicebio’s proprietary molecular clamp technology, designed to improve how the immune system identifies and responds to viral proteins. This innovative approach could enhance the efficacy of next-generation vaccines by stabilizing viral proteins in their pre-fusion state, a critical target for immune responses.

Sanofi stated that the acquisition is expected to close in the fourth quarter of 2025, subject to customary regulatory approvals. The company also noted that the transaction will not materially affect its full-year earnings guidance.

This move aligns with Sanofi’s broader strategy of investing in cutting-edge vaccine technologies and reinforcing its pipeline through targeted biotech acquisitions. As respiratory diseases continue to pose global health challenges, the addition of Vicebio’s assets may provide a competitive edge in developing advanced vaccines to meet rising healthcare demands. The deal also underscores the increasing interest among big pharma in innovative vaccine platforms and emerging biotech talent.